Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call Transcript
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator instructions) I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Thank you, Amy, and good afternoon, everyone, and thank you for joining us today to discuss Arrowhead's results for fiscal 2024 first quarter ended December 31, 2023. With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter. We also welcome back Dr. Bruce Given who previously served as Arrowhead's Chief Operating Officer and Head of R&D and who has rejoined the company on an interim basis as chief medical scientist. Bruce will provide an update on our cardiometabolic pipeline, Dr. James Hamilton, our Chief of discovery and translational medicine will provide an update on our earlier-stage programs, and Ken Myszkowski, our Chief Financial Officer, will give a review of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |